Prevalence of *Chlamydia trachomatis* and *Mycoplasma genitalium* in pregnant women of Sabzevar- Iran

Haghighi Hasanabad M¹, Mohammadzadeh M¹, Bahador A², Fazel N¹, Rakhshani H¹, Majnooni A³

¹Molecular and Cellular Biology Research Center, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran. ²Departments of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ³Research center of Infectious and Tropical Disease, Tabriz University of Medical Sciences, Tabriz, Iran.

Received: June 2011, Accepted: August 2011.

**ABSTRACT**

**Background:** As prenatal screening for sexually transmitted infections and treatment of infected pregnant women is not routinely performed in Iran and prevalence of two sexually transmitted pathogens, *Chlamydia trachomatis* and *Mycoplasma genitalium*, in Sabzevar (east of Iran) is unknown, we decided to perform this prospective study.

**Methods:** One hundred ninety-six urine specimens of pregnant women attending the specialized maternity hospital of the city were collected and tested by duplex PCR.

**Results:** A total of 31 specimens were positive (15.81%) (27 *Chlamydia trachomatis* isolates, 13.77%; and 2 *Mycoplasma genitalium* isolates, 1.02%). Co-infection with both species was detected in 2 specimens (1.02%). A significant correlation was found between preterm labor and infection (P-value ≤ 0.05).

**Conclusion:** The present study shows high prevalence of Chlamydial infections in comparison with *Mycoplasma genitalium* in this region. Further studies with larger sample size and more focused on different groups at risk are needed for a movement towards prevention and control of sexually transmitted infections (STIs).

**Keywords:** Prevalence, *Chlamydia trachomatis*, *Mycoplasma genitalium*, Pregnant women

**INTRODUCTION**

There are more than 30 different sexually transmissible agents and the most common treatable and preventable of them is *Chlamydia trachomatis*. Rapid detection of Chlamydial infections in the medical laboratory is very important. Epidemiologic studies have indicated that the most serious sequela occur in women are pelvic inflammatory disease (infection in the fallopian tubes) and ectopic pregnancy (pregnancy in the tubes) (1). In addition, several reports have suggested that untreated maternal cervical chlamydial infection increases the risk of preterm delivery, premature rupture of membranes (PROM), and prenatal mortality or stillbirth (2). In newborns, infection can occur as a result of prenatal exposure; approximately 65% of babies born from infected mothers become infected during vaginal delivery. Infections caused by *C. trachomatis* are particularly difficult to confine as a high proportion of these infections are asymptomatic, thus making part of the population (those not tested) a reservoir for further transmission (3).

*Mycoplasma genitalium* (*M. genitalium*) which was discovered in the early 1980s has proved itself as a significant pathogen. It is similar to *C. trachomatis* in several respects such as preference for the genital...
tract, mode of transmission, making various adverse
gynecologic and reproductive events and cervicitis
(4). It has been implicated as an etiological agent of
pelvic inflammatory disease (PID) independent of
*C. trachomatis* and *Neisseria gonorrhoeae* (5). Also in
one study, an association has been reported between
*M. genitalium* and preterm delivery (6).

Screening of *C. trachomatis* with cell culture as a
gold standard is very difficult and requires specimens
from urogenital swabs, which are unacceptable to
many people. Urine samples have cytotoxic effect
and are not suitable for culture. Other routine tests for
*Chlamydia*, such as enzyme immunoassays, have low
sensitivity in asymptomatic individuals. Detection of
*M. genitalium* by the culture method is also very
time-consuming and requires up to 8 weeks for this
microorganism whereas the nucleic acid amplification
techniques can detect infectious agents in less than 8
hours (7).

Because of difficulties in cultivation of these
fastidious organisms, some 15 years ago, a great deal
of research has led to the development and evaluation
of sensitive and specific diagnostic tests based on
nucleic acid amplification tests. The important
aspect of these assays was their capacity to be used
on non-invasive specimens such as first void urine
(FVU), which can be self-collected. Therefore it
facilitates larger investigations on prevalence in many
populations (8).

Nucleic acid amplification tests showed > 95%
sensitivity and specificity for detection of *M.
genitalium* and *C. trachomatis* from urine samples
(9). More recently, different PCR methods have been
developed to detect STI-causing organisms. One of
these methods is multiplex PCR (mPCR), which is a
single step method that employs one tube containing
PCR mixture and permits the simultaneous detection
of more than one organism. This method has been used
to detect multiple bacterial STIs in clinical specimens
(10). This mPCR assay will be a more time- and
cost-efficient diagnostic tool than the other currently
employed techniques. Specificity and sensitivity
of this method for detection of *C. trachomatis*
and *M. genitalium* were estimated to be 100% and
98.9%, respectively (11). The aim of this study was
to investigate the prevalence of *C. trachomatis* and
*M. genitalium*, and related risk factors in pregnant
women for the first time in Sabzevar city.

**MATERIALS AND METHODS**

One hundred ninety-six urine samples of pregnant
women (< 50 years old; in second or third trimesters
of pregnancy) attending in the only maternity hospital
(Mobini Martyr Hospital) of Sabzevar city, from
September 2010 to February 2011 were screened for
eligibility. Participants were ineligible if they had
antibiotic use in the last 3 weeks, kidney disease,
catheter usage, cognitive impairment, and illness
severity that precluded study interview (12).

Two trained research assistants obtained the
following information from each participant through
a specific questionnaire and face-to-face individual
interview: socio-demographic data (age, education,
and residence), current history of clinical signs and
urogenital symptoms (preterm labor, dysuria, urinary
urgency, urinary frequency, vaginal discharge, vaginal
itching) and sexual history (history of STIs, history of
abortion, history of preterm delivery).

The research ethics board at Sabzevar University of
Medical Sciences approved this research project and
all participants signed a consent form.

10 ml of First Void Urine (FVU) were collected
at least two hours after last urination in a sterile
container. Samples were not frozen before testing but
maintained at 4°C for one night in order to decrease
inhibitors in urine (13). Finally, samples on ice were
transported to the research laboratory. Immediately
samples were centrifuged in 4°C (6000 g for 30min)
and pellets were washed with PBS (Phosphate Buffer
Saline) twice and prepared for DNA extraction by
DNG-Plus kit (Cinnagen, Tehran, Iran) according to
the manufacturer’s protocol. Extracted DNAs were
stored at -70°C (14).

**Table 1. Primers used for duplex PCR.**

| Species           | Forward                     | Sequences       | Reverse                     |       |
|-------------------|----------------------------|------------------|-----------------------------|-------|
| *C. trachomatis*  | 5’- CTAGGCGTTTGTACTCCGTCA -3’| 200bp            | 5’- TCCTCAAGGATTTATGCACT -3’|       |
| *M. genitalium*   | 5’- AGTTGATGAAACCTTAACCCCTT-3’| 346bp            | 5’- CAATTACAGTTAAACCAAGCCT -3’|       |
PREVALENCE OF C. TRACHOMATIS & M. GENITALIUM IN SABZEVAR

Table 1 shows the sequences of primers used to amplify a specific 200 bp fragment of the Orf 8 gene of C. trachomatis and primers were used for a specific 346 bp fragment of the conserved part of MgPa adhesion gene (MG192) of M. genitalium (15).

Initially, to establish the conditions for Duplex PCR, we set up uniplex PCR using positive control DNA from C. trachomatis serovar L2 type strain 434/Bu (ATCC VR-902B) and M. genitalium type strain G37 (ATCC 35350). Amplification reactions were performed in a volume of 20 μl containing 1 μl of extracted DNA. The reaction involved one cycle at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 54°C or 56°C for 35 sec, and extension at 72°C for 30 sec followed by one last cycle at 72°C for 8 min. The reactions were performed on a PCR system (Techne, UK).

Subsequently, duplex PCR conditions were established using a mixture of DNA from both control bacterial strains. The 40 μl Duplex PCR reaction mixture consisted of 1 μl from each extracted DNAs, 4 μl of the master mix solution, 0.5 μl of each specific oligonucleotide primer.

The reaction for the uniplex PCR was the same except that annealing temperature was 55°C. Once the Duplex PCR conditions had been optimized, the 196 FVU samples were subjected to Duplex PCR. In addition, negative controls lacking DNA and positive controls consisting 300 ng of genomic DNA from each bacterial strains were tested. The PCR products were analyzed by electrophoresis in the 0.5% TBE buffer through 1% agarose gel, stained with ethidium bromide, and DNA bands visualized using a UV transilluminator.

The collected data were entered into a computer using SPSS, version 15. The statistical relationship between the risk factors and infection were assessed using the chi-squared test.

RESULTS

We recruited 196 pregnant women between September 2010 and February 2011 and 10 women (5% of total subjects) inevitably were excluded from the study. Subjects ranged in age from 17–45 years (mean 31.0 years); and a high proportion of women were below 30 years old which represented about 66.8% of all cases (Table 2). In this study, 74.4% of participants lived in the city and 65.8% of them did not have children. Also, 37.2% had at least one or more symptoms referable to the genito-urinary tract at time of interview. Vaginal discharge, urinary frequency and vaginal itching were common current clinical symptoms in all pregnant women.

A statistical association was seen significantly between preterm labor and infection in this study (P-value ≤ 0.05). Also data analyses suggest a possible positive correlation of infection with history of abortion in pregnant women (P value ≤ 0.1). Of 196

| Risk factors | Infected | % | Not-infected | % | Total | P-Value |
|--------------|----------|---|--------------|---|-------|---------|
| Age years old 30 > | 22 | 11.2% | 109 | 55.6% | 131 | NS |
| Education | 9 | 4.5% | 56 | 28.5% | 65 | NS |
| Illiterate/High school | 24 | 12.2% | 144 | 73.4% | 168 | NS |
| Diploma/university degree | 7 | 3.5% | 21 | 10.7% | 28 | |
| Symptoms | | | | | | |
| Yes | 11 | 5.6% | 62 | 31.6% | 73 | |
| No | 20 | 10.2% | 103 | 52.5% | 123 | |
| Preterm Labor | | | | | | |
| Yes | 4 | 2.0% | 52 | 26.5% | 56 | P ≤ 0.05 |
| No | 27 | 13.7% | 113 | 57.6% | 140 | |
| History of STIs | | | | | | |
| Yes | 5 | 2.5% | 19 | 9.6% | 24 | NS |
| No | 26 | 13.2% | 146 | 74.4% | 172 | |
| History of Abortion | | | | | | |
| Yes | 3 | 1.5% | 37 | 18.8% | 40 | P ≤ 0.1 |
| No | 28 | 14.2% | 128 | 65.3% | 156 | |

NS: Not Significant
women, 31 (15.81%) were positive in PCR test. *C. trachomatis* was detected in 27 samples (13.77%) and *M. genitalium* was positive in two samples (1.02%). Also co-infection was seen in two samples (1.02%).

Table 2 illustrates statistical analysis results of important variables in this study.

**DISCUSSION**

There were several studies conducted in Iran that reported the prevalence of *C. trachomatis* to be from 2% to 11%. Only in one study 5.2% of pregnant women were reported to be infected with *M. genitalium*. It is worth noting that the diagnostic tests varied in the different studies and could contribute to the differences in the reported prevalence rates. Many studies have found that nucleic acid amplification tests are sufficiently sensitive to detect *C. trachomatis* and *M. genitalium* in first-void urine of women. Sensitivities have exceeded 95% in most studies when compared to detection with non-culture methods of endocervical specimens as a standard, while at the same time preserving high specificities (16).

The prevalence of *C. trachomatis* reported in this study (14.79%) is high in comparison with the moderate rates reported by other studies in Tehran, Iran (11.1% and 11.2% respectively) in similar study subjects and settings (17, 18). In two different studies conducted with Direct Immunoflourescent assay and ELISA consecutively in Bandarabbas and Ahvaz, south & south-west of Iran, the prevalence of *C. trachomatis* infection were reported to be 5.2% and 10% in pregnant women respectively (19, 20). In addition, two other studies from Tehran with similar methods (Direct Immunoflourescent and ELISA) report 2.7% and 2.9% Chlamydial prevalence in pregnant women (21, 22). *C. trachomatis* prevalence differs by treatment practices in different areas, but it seems that use of low sensitivity methods are the main reason for significant difference in prevalence rate reported from Tehran.

Depending on health status, the existence of symptoms and risky behavior of individuals, the prevalence of STIs in women differ from one country to another. Numerous surveys have been carried out to study the prevalence of *C. trachomatis* infection and risk factors among pregnant women or women attending antenatal clinics. *C. trachomatis* infection rate in our study is moderate in comparison to those found in several other countries: 10.1% in China, 10.5% in Saudi Arabia, 12.1% in Scotland, 35% in India (23-26).

In this study, *M. genitalium* was detected in 2.04% of participants, which illustrates a low percentage of occurrences in this region. In one study, performed by duplex PCR assay for simultaneously detection of *M. genitalium* and *Ureaplasma Urealyticum* in pregnant and non pregnant women of Tehran, the prevalence of *M. genitalium* was 5.2% (11/210) in total (27). The difference in the results of these two studies may be contributed to the type of subjects (pregnant vs. non-pregnant) and the sample type (urine vs. swabs). Also prevalence of *M. genitalium* in this study is similar to one study in Canada, with 3.6% infection in pregnant women (28).

Previous epidemiological investigations for *C. trachomatis* in pregnant women have revealed various associated risk factors for infection including age (in particular 18-27 years) and socio-economic status factors like urban residency or low-income (29). In this study, 75.8% of pregnant women with positive test results were less than 30 years old and 72.4% of infected women lived in the city, which confirmed results of previous research. Also in our study, a significantly higher detection rate of *C. trachomatis* infection was observed among primigravida (82.7%) compared to, multigravida (17.3%) and is similar to results of one study in Japan that demonstrated the prevalence of *C. trachomatis* was significantly higher among this group (primigravida) of pregnant women (30).

Based on several studies, one of the leading causes of prenatal mortality is prematurity. Asymptomatic bacteriuria, gonococcal cervicitis and bacterial vaginosis are strongly associated with preterm delivery, but the role of *C. trachomatis* was less clear (31). Recently, new studies report that infections with *C. trachomatis* are associated with premature delivery in pregnancy and our findings confirmed this (32, 33).

In many studies, researchers have indicated *C. trachomatis* infection as a risk factor in abortion, prenatal mortality and stillbirth (34). Although a weak association was seen in this study (Table 2), which confirmed this relationship, more studies with larger sample size in longer follow-ups are needed to investigate this factor during pregnancy and its outcome.

The rate of complications following a *C. trachomatis* infection is of crucial importance when evaluating
cost-effectiveness in screening programs. Health care costs after a *C. trachomatis* infection in the United States have been estimated to exceed US $2 billion per year (35).

The Iranian health care system needs to revise the antenatal care offered and factors that encourage the utilization of antenatal services, such as offering the services free of charge, providing incentives, health promotion and adequate postnatal services.

**CONCLUSION**

The prevalence obtained in this study is relatively high. In our region (east of Iran), there are no data about *C. trachomatis* and *M. genitalium* in pregnant women and this is the first study conducted in Sabzevar city. However, further studies with larger sample size and more focused on different groups at risk are needed for movement towards prevention and control of STIs.

**ACKNOWLEDGMENT**

The authors thank the Shahid Mobini Hospital administrators in Sabzevar. The authors also thank Ms Kalantari and Ms Delghandi for their assistance. This work was supported by Sabzevar University of Medical Sciences.

**REFERENCES**

1. Alger LS, Lovchik JC, Hebel JR, Blackmon LR, Crenshaw MC. The association of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and group B streptococci with preterm rupture of membranes and pregnancy outcome. *Am J Obstet Gynecol* 1988; 159: 397-404.
2. Martius J, Krohn MA, Hillier SL, Stamm WE, Holmes KK, Eschenbach DA. Relationship of vaginal *Lactobacillus* species, cervical *Chlamydia trachomatis* and bacterial vaginosis to preterm birth. *Obstet Gynecol* 1988; 71: 89-95.
3. Kelly M. Researchers design unique method to induce immunity to certain STDs. In: Health & Medicine. University of California, Los Angeles (UCLA). 2009; published online Thursday, April 30.
4. Vanessa LS, Jorgen SJ, Deborah BN, Pamela JM, Roberta BN, Catherine LH. *Mycoplasma genitalium* among young, urban pregnant women. Infectious Diseases in Obstetrics and Gynecology. Volume 2010 (2010), Article ID 984760, 8 pages doi: 10.1155/2010/984760.
5. Oakeshott P, Hay P, Taylor-Robinson D, Hay S, Dohn B, Kerry S, et al. Prevalence of *Mycoplasma genitalium* in early pregnancy and relationship between its presence and pregnancy outcome. *BJOG* 2004; 111: 1464-1467.
6. Witkin SS, Ledger WJ. Antibodies to *Chlamydia trachomatis* in sera of women with recurrent spontaneous abortions. *Am J Obstet Gynecol* 1992; 167: 135-139.
7. Mardh PA, Colleen S, Sylvan J. Inhibitory effect on the formation of chlamydial inclusions in McCoy's cells by seminal fluid and some of its components. *Investig Urol* 1980; 17: 510-517.
8. Jensen JS, Bjornelius E, Dohn B, Lidbrink P. Comparison of first void urine and urogenital swab specimens for detection of *Mycoplasma genitalium* and *Chlamydia trachomatis* by polymerase chain reaction in patients attending a sexually transmitted disease clinic. *Sex Transm Dis* 2004; 31: 499-507.
9. Weinstein SA, Stiles BG. A review of the epidemiology, diagnosis and evidence-based management of *Mycoplasma genitalium*. *Sexual Health* 2011; 8: 143-158.
10. Jaschek G, Gaydos CA, Welsh LE, Quinn TC. Direct detection of *Chlamydia trachomatis* in urine specimens from symptomatic and asymptomatic men by using a rapid polymerase chain reaction assay. *J Clin Microbiol* 1993; 31: 1209-1212.
11. Mahony JB, Jang D, Chong S, Luijnstra K, Sellors J, Tyndall M, Chernesky M. Detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Ureaplasma urealyticum*, and *Mycoplasma genitalium* in first-void urine specimens by multiplex polymerase chain reaction. *Mol Diagn* 1997; 2: 161-168.
12. Huppert JS, Biro F, Lan D, Mortensen JE, Reed J, Slap GB, et al. Urinary symptoms in adolescent females: STI or UTI? *J Adolesc Health* 2007; 40: 418-424.
13. Shafer MA, Moncada J, Boyer CB, Betsinger K, Flinn SD, Schachter J, et al. Comparing first-void urine specimens, self-collected vaginal swabs, and endocervical specimens to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* by a nucleic acid amplification test. *J Clin Microbiol* 2003; 41: 4395-4399.
14. Cheng H, Macaluso M, Vermund SH, Hook EW. Relative accuracy of nucleic acid amplification tests and culture in detecting *Chlamydia* in asymptomatic men. *J Clin Microbiol* 2001; 39: 3927-3937.
15. Lee SR, Chung JM, Kim YG. Rapid one step detection of pathogenic bacteria in urine with sexually transmitted disease (STD) and prostatitis patient by multiplex PCR assay (mPCR). *J Microbiol* 2007; 45: 453-459.
16. Jeddil-Tehrani M. Diagnosis Methods of *Chlamydia trachomatis*. *J Reprod Infertil* 2000; 1: 36-43.
17. Rashidi B, Chamani L, Haghollahi F, Ramezanzadeh F, Shariat M, Rahimi FA, et al. Prevalence of *Chlamydia trachomatis* infection in fertile and infertile women: A molecular and serological study. *J Reprod Infertil* 2009; 10: 32-41.
18. Chamani L, Tehranzi MJ, Zeraati H, Asgari S, Moini M, Rabbani H, et al. A Molecular survey on prevalence of *Chlamydia trachomatis* infection in pregnant woman attending OB&GY clinics of Tehran. *Iran J Infect Dis Trop Med* 2007; 13: 45-50.
19. Jahromi AS, Farjam MR, Mogharrab F, Amiryan M,
Makiani MJ, Madani A, et al. *Chlamydia trachomatis* in Women with Full-Term Deliveries and Women with Abortion. *Am J Infect Dis* 2010; 3: 66-69.

20. Sohrabi A, Samarbazadeh A, Makvandi M, Maraghi Sh, Razi T, Darban D, et al. A seroepidemiological study of parvovirus B19, *Toxoplasma gondii* and *Chlamydia trachomatis* in pregnant women referring to Obs & Gyn ward of Ahwaz Imam Khomeini Hospital. *J Reprod Infertil* 2007; 8: 171-175.

21. Badami N, Salari MH. Rate of *Chlamydia trachomatis*, *Mycoplasma hominis* and *Ureaplasma urealyticum* in infertile females and control group. *Iran J Public Health* 2001; 30: 57-60.

22. Khezerdoust S, Haghollahi F, Roostaie S, Badami N, Naghizadeh MM, Jafarabadi M, et al. *Chlamydia trachomatis* infection in pregnant women. *J Reprod Infertil*. 2009;10 (2):121-128.

23. Borges da Costa J, Azevedo J, Santo I. Sexually transmitted infections and related sociodemographic factors in Lisbon’s major venereology clinic: A descriptive study of the first 4 months of 2007. *J Eur Acad Dermatol Venereol* 2010; 24: 811-814.

24. Chen XS, Yin YP, Chen LP, Thuy NT, Zhang GY, Shi MQ, et al. Sexually transmitted infections among pregnant women attending an antenatal clinic in Fuzhou, China. *Sex Transm Dis* 2006; 33: 296-301.

25. Alzahrani AJ, Obad OE, Hassan ML, Almulhim AA. Screening of pregnant women attending the antenatal care clinic of a tertiary hospital in eastern Saudi Arabia for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections. *Indian J Sex Transm Dis* 2010; 31: 81-86.

26. Sharma M, Sethi S, Daftari S, Malhotra S. Evidence of chlamydial infection in infertile women with fallopian tube obstruction. *Indian J Pathol Microbiol* 2003; 46: 680-683.

27. Mirnejad R, Amirmozafari N, Kazemi B. Simultaneous and rapid differential diagnosis of *Mycoplasma genitalium* and *Ureaplasma urealyticum* based on a polymerase chain reaction-restriction fragment length polymorphism. *Indian J Med Microbiol* 2011; 29: 33-36.

28. Luki N, Lebel P, Boucher M, Doray B, Turgeon J, Brousseau R. Comparison of polymerase chain reaction assay with culture for detection of genital mycoplasmas in perinatal infections. *Eur J Clin Microbiol Infect Dis* 1998; 17: 255-63.

29. Singh V, Rastogi S, Garg S, Kapur S, Kumar A, Saltan S, et al. Polymerase chain reaction detection for detection of endocervical *Chlamydia trachomatis* infection in women attending a gynecology outpatient department in India. *Acta Cytol* 2002; 46: 540-544.

30. Shimano S, Nishikawa A, Sonoda T, Kudo R. Analysis of the prevalence of bacterial vaginoses and *Chlamydia trachomatis* infection in 6083 pregnant women at a hospital in Otara. *Jpn J Obstet Gynaecol Res* 2004; 30: 230-236.

31. Cram LF, Zapata MI, Toy EC, Baker B. Genitourinary infections and their association with preterm labor. *Am Fam Physician* 2002; 65: 241-248.

32. Rours G, Duijts L, Moll HA, Arends LR, de Groot R, Jaddoe V, et al. *Chlamydia trachomatis* infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. *Eur J Epidemiol* 2011; 26: 493-502.

33. Odendaal HJ, Schoeman J, Grove D, Jager de M, Theron GB, Ortth H, et al. The association between *Chlamydia trachomatis* genital infection and spontaneous preterm labour. *S Afr J Obstet Gynaecol* 2006; 12:146-149.

34. Wilkowska-Trojniel M, Zdrodowska-Stefanow B, Ostaszewska-Puchalska I, Redzko S, Przepiesz J, Zdrodowski M. The influence of *Chlamydia trachomatis* infection on spontaneous abortions. *Adv Med Sci* 2009; 54: 86-90.

35. Oakeshott P, Kerry S, Aghaiizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for *Chlamydia trachomatis* to prevent pelvic inflammatory disease: the POPPI (prevention of pelvic infection) trial. *BMJ* (Clinical research ed.340: c1642.